Want to see IRON full AI Analyst Report?
IRON Stock Chart & Stats
$82.41
$0.49(0.66%)
At close: 4:00 PM EDT
$82.41
$0.49(0.66%)
Day’s Range― - ―
52-Week Range$40.00 - $99.50
Previous Close$74.61
Volume355.43K
Average Volume (3M)893.85K
Market Cap
$3.03B
Enterprise Value$2.17B
Total Cash (Recent Filing)$717.75M
Total Debt (Recent Filing)$60.86M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 05, 2026EPS Estimate
-1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.60
Shares Outstanding38,392,845
10 Day Avg. Volume1,496,063
30 Day Avg. Volume893,847
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.99
Forecast
1Y Price Target
$119.20Price Target Upside44.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-6.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 ValidationPositive Phase 3 results materially strengthen bitopertin’s probability of regulatory success and provide clinical validation for Disc’s lead program. The planned NDA resubmission creates a defined path toward potential commercialization and future revenue in a serious rare disease.
Pipeline BreadthDISC-3405 adds a second clinically meaningful development opportunity beyond bitopertin. Sustained hematocrit control and fewer phlebotomies support potential patient value, while progress toward pivotal development could diversify the company’s future product and revenue base.
Low LeverageVery low leverage gives Disc financial flexibility while it advances multiple clinical programs and prepares for potential commercialization. The substantial equity base reduces dependence on debt financing and provides a stronger cushion against execution setbacks than a highly leveraged balance sheet.
Bears Say
Pre-revenue ModelDisc has no commercial revenue to offset its research, development, and operating expenses, leaving financial performance dependent on clinical progress and future product approval. Until a candidate reaches the market, widening losses will continue to limit operating leverage and earnings visibility.
Heavy Cash BurnThe scale of ongoing cash outflows makes continued external financing important for maintaining the development portfolio and commercialization preparation. Persistent negative free cash flow can reduce financial flexibility over time, particularly if clinical or regulatory timelines extend.
Equity Financing DilutionThe proposed equity financing can extend development funding, but issuing common shares or warrants increases the potential share count for existing investors. This underscores the company’s continuing need for capital before revenues begin and may dilute ownership as programs advance.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $40.00 and its highest was $99.50 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $3.03B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Jul 30, 2026. The company reported -$1.54 earnings per share for the quarter, beating the consensus estimate of -$1.713 by $0.173.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.63.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 38,392,845 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.54 in its last earnings report, beating expectations of -$1.713. Following the earnings report the stock price went up 7.52%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.20 (44.64% Upside)
$119.20 (44.64% Upside)
Blogger Sentiment
Neutral
IRON Sentiment 54%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 476.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.82%
12-Months-Change
Fundamentals
Return on Equity
-37.17%
Trailing 12-Months
Asset Growth
10.53%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Disc Medicine
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
IRON Stock 12 Month Forecast
Average Price Target
$119.20
▲(44.64% Upside)
Technical Analysis
Ownership Overview
8.91% Insiders
27.14% Mutual Funds
3.01% Other Institutional Investors
48.40% Public Companies and
Individual Investors